CPA
BMRN icon

Cowen Prime Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cowen Prime Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,000
Closed -$141K – 274
2013
Q4 		$141K Buy
2,000
+1,000
+100% +$67.9K 0.05% 118
2013
Q3 		$72K Buy
+1,000
New +$66.5K 0.03% 166

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cowen Prime Advisors's BMRN Position: Q1 2014 in Review

Cowen Prime Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2014, closing a stake of 2,000 shares — an estimated $141K sold.

Cowen Prime Advisors first reported a position in BMRN in Q3 2013 and held it in 2 quarters. The position peaked at $141K in Q4 2013. 313 funds tracked by Wall St. Rank hold BMRN as of Q1 2014.

  • Cowen Prime Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Cowen Prime Advisors sold 2,000 BioMarin Pharmaceuticals shares in Q1 2014, an estimated $141K.
  • Cowen Prime Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • Cowen Prime Advisors's BioMarin Pharmaceuticals position peaked at $141K in Q4 2013.
  • 313 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2014.

Based on Cowen Prime Advisors's 13F filing for Q1 2014, filed 13 May 2014.